Rasmussen JJ, Albrethsen J, Frandsen MN, et al. - In this community-based cross-sectional study, researchers sought to examine serum insulin-like factor 3 (INSL3) concentrations in anabolic androgenic steroids (AAS) users. They involved men aged 18 – 50 years, included in recreational strength training and allocated to one of three groups: never-AAS users as controls (n = 44), current (n = 46) or former AAS users (n = 42) with an average duration since AAS cessation of 32 (23;45) months. Serum INSL3 is reduced years after the cessation of AAS in men, independently of testosterone, indicating persistently impaired Leydig cell capacity.